## Not the 2020 we asked for

Vishal Jhanji 💿 ,<sup>1</sup> James Chodosh 💿 <sup>2</sup>

2020 was poised to be the year when the larger ophthalmic community, including academia and industry, would showcase its accomplishments and eye care advances. Unfortunately, 2020 has become the year that a viral pandemic upended everything, leaving scores dead and many more severely ill. Life as we knew it is on hold and will never be the same for many of us. The COVID-19 pandemic presents the biggest challenge our generation has ever faced. In this context, it is encouraging that physicians and scientists around the world have continued to push forward with research targeted to understand and ultimately defeat the infection. Chen et al present the clinical findings and outcome of a patient who developed mild follicular conjunctivitis during his COVID-19 infection.<sup>1</sup> Tear samples taken from the patient after onset of conjunctivitis were positive by reverse transcription PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus that causes COVID-19. Repeated tear sampling revealed a downward trend which

matched a gradual improvement of ocular symptoms. A recent study of 30 patients (60 eyes) hospitalised for COVID-19 in China reported SARS-CoV-2 in the ocular secretions of both eyes of the only patient with conjunctivitis, but not in the 29 patients (58 eyes) without signs of conjunctivitis.<sup>2</sup> In another study. researchers documented conjunctival 'congestion' in 9 of 1099 patients (0.8%) with laboratory-confirmed COVID-19 from 30 hospitals across China,<sup>3</sup> suggesting that  $\sim 1\%$  of patients with COVID-19 may develop conjunctivitis. As of 26 March 2020, there were over 460000 known cases of COVID-19. That would translate to ~4600 patients with COVID-19 conjunctivitis that could be seen by ophthalmologists. These data confirm the potential risk to ophthalmologists when examining a COVID-19 patient with conjunctivitis and should offer reassurance to those performing eye examinations of COVID-19 patients without conjunctivitis that patient tears are an unlikely source of transmission. As more reports emerge,<sup>45</sup> we should soon have a clearer picture of the ocular findings associated with COVID-19 and the potential risks encountered by ophthalmologists in the care of affected patients, so that our view going forward will indeed be 20/20.

Contributors Both authors contributed equally.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Jhanji V, Chodosh J. *Br J Ophthalmol* 2020;**104**:741. Published Online First 10 April 2020



► http://dx.doi.org/10.1136/bjophthalmol-2020-316304

*Br J Ophthalmol* 2020;**104**:741. doi:10.1136/bjophthalmol-2020-316403

## ORCID iDs

Vishal Jhanji http://orcid.org/0000-0002-4429-2004 James Chodosh http://orcid.org/0000-0002-7463-1599

## REFERENCES

- Chen Let al. Ocular manifestations of a hospitalized patient with confirmed 2019 novel coronavirus disease. Br J Ophthalmol 2020;104:748–51.
- 2 Xia J, Tong J, Liu M, *et al*. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *J Med Virol* 2020. doi:10.1002/ jmv.25725. [Epub ahead of print: 26 Feb 2020].
- 3 Guan W-jie, Ni Z-yi, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020.
- 4 Wang D, Hu B, Hu C, *et al.* Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. *JAMA* 2020. doi:10.1001/jama.2020.1585. [Epub ahead of print: 07 Feb 2020].
- 5 Huang C, Wang Y, Li X, *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.

<sup>&</sup>lt;sup>1</sup>Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States <sup>2</sup>Ophthalmology, Massachusetts Eye and Ear, Howe Laboratory, Harvard Medical School, Boston, Massachusetts, United States

**Correspondence to** Vishal Jhanji, Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States; jhanjiv@pitt.edu